Henry Meds vs Mochi Health: Medication Access and Fulfillment

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This comparison is part of the PlexusDx Education Hub, our resource on GLP-1 therapy, weight-management protocols, and the genetics behind them. Open the Peptides & GLP-1 hub.

Independent editorial review. PlexusDx has no commercial relationship with Henry Meds or Mochi Health, and no affiliate links or referral fees are involved.

Full head-to-head: PlexusDx vs Henry Meds →

When people compare Henry Meds and Mochi Health, the practical question is usually about the medication itself — where it comes from, how it is fulfilled, and what pathway each program uses to get it to you. This review focuses on that access-and-fulfillment layer, then turns to a genetic factor neither program measures. Current as of April 2026.

Where your medication actually comes from

The heart of this comparison is fulfillment. Both programs prescribe GLP-1 therapy, but they route it differently: one leans toward a compounding-pharmacy pathway, the other adds insurance support that can point toward retail, FDA-approved product. Understanding those routes tells you more than any brand tagline. For a query centered on the medication itself, the fulfillment route is the real substance, not the logo on the checkout page or the name at the top of the site.

How Henry Meds dispenses

Henry Meds (Henry Meds) is structured around telehealth paired with a compounding-pharmacy pathway. A program of this shape pairs a virtual evaluation with a provider-issued prescription dispensed through a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Confirm the current medication list and fulfillment details on Henry Meds' official website.

How Mochi Health dispenses

Mochi Health (Mochi Health) operates as telehealth with insurance support. Depending on eligibility, a prescription may route to a retail pharmacy for FDA-approved medication or to a 503A compounding pharmacy for a compounded product. The specifics are posted on Mochi Health's official website and can change over time.

Retail, compounded, and the 503A pathway

Two fulfillment lanes exist. FDA-approved branded GLP-1 products are dispensed by retail pharmacies; compounded semaglutide and tirzepatide are prepared by 503A pharmacies for an individual prescription. The lane a program uses affects cost, availability, and how the medication is packaged — which is exactly the difference the "meds" question is getting at.

The compound sets the pharmacology, not the platform

Regardless of fulfillment lane, the biology is identical. GLP-1 receptor agonists like semaglutide and the dual agonist tirzepatide act on appetite, satiety, and gastric emptying. Whether a medication arrives from a retail counter or a compounding pharmacy, its effect is a property of the molecule — not of the telehealth brand that arranged it.

The genetic map neither service provides

What no fulfillment pathway accounts for is your inherited biology. An FTO variant shapes appetite and fat-mass regulation, GLP1R encodes the receptor these compounds act on, and MC4R anchors satiety signaling. The PlexusDx Precision Peptide Genetic Test examines 14 pathways, 49 peptides, 150+ genetic insights across that biology — mapping your baseline terrain rather than predicting how any specific medication will perform.

How PlexusDx handles access with context

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection at $189/month, Tirzepatide Injection at $289/month — paired with the Precision Peptide Genetic Test. The medication access comes with pathway data attached, so decisions start from your biology. Test before you invest.

No affiliation: PlexusDx is unaffiliated with Henry Meds and Mochi Health and has no commercial relationship with either.

More PlexusDx reading: GLP 1 Drugs, GLP 1 Hormone, GLP 1 Receptor Agonist, and What Is GLP 1.

Editorial note: this comparison is educational and independent. PlexusDx has no relationship with Henry Meds or Mochi Health and provides semaglutide and tirzepatide through its own protocols. The Precision Peptide Genetic Test analyzes gene-influenced peptide pathways and does not predict medication response. Consult a qualified provider before starting any peptide protocol.

Frequently Asked Questions

Where do Henry Meds and Mochi Health get their medication?

Henry Meds emphasizes a 503A compounding-pharmacy pathway for compounded semaglutide or tirzepatide, while Mochi Health's insurance support can route eligible prescriptions toward retail, FDA-approved products. The exact fulfillment for each depends on eligibility and current program terms posted on their own websites.

Is compounded medication the same as the branded drug?

They share the same GLP-1 mechanism but differ in sourcing. Compounded semaglutide and tirzepatide are prepared by a 503A pharmacy for an individual prescription, while branded products are FDA-approved and dispensed at retail. Cost, availability, and packaging differ between the two fulfillment pathways.

Does fulfillment pathway affect how the medication works?

No. The pharmacology comes from the compound, so a properly dispensed GLP-1 medication acts the same whether it arrives through a retail pharmacy or a compounding pharmacy. What the pathway changes is cost, access, and availability — not the underlying biological effect of the molecule.

How does genetic testing relate to medication access?

The Precision Peptide Genetic Test does not predict drug response or dictate a fulfillment pathway. It maps pathway variants like FTO, and MC4R that describe your metabolic baseline, adding context you can bring to a provider no matter which program supplies your medication.

This article is part of the PlexusDx Education Hub. Browse more Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.